BIO-NMD: biomarker research

BIO-NMD: biomarker research
  • Contact
  • Alessandra Ferlini
    Alessandra Ferlini
    Alesandra Ferlini is a professor in medical genetics, director of the Medical Genetics section at...
  • Cathy Turner
    Cathy Turner
    Cathy Turner is Duchenne Programme and TACT Coordinator at the John Walton Muscular Dystrophy Research...

BIO-NMD (contract no. 241665), led by Professor Alessandra Ferlini (Ferrara), was a research project on biomarker research and discovery that was funded by the European Union’s Seventh Framework Programme in January 2010.

Biomarkers are measurable bio-parameters that can be used to monitor disease progression, prognosis and drug response, thus optimizing the choice of appropriate and often personalized therapies. Early-stage clinical trials are typically so short that they provide limited opportunity to evaluate whether there is a meaningful clinical improvement. The identification of surrogate endpoints to help detect the activity of a new therapy in the early stages of development is essential to rapid progress on the development path.

BIO-NMD aims to discover and validate new genomic and proteomic biomarkers, which will be validated both in animal models and in human samples before entering into a qualification process at the EMA.

Funding for this project ended in 2012 however the website is still available to visit.

12 Apr 2017